Trial first to show immunotherapy benefit in prostate cancer

Adjust Comment Print

"However, numerous men who was on the verge of death, was able to beat cancer due to this drug and more than 18 months they have not shown any of the signs of secondary cancer of the prostate". The drugs alter the body's immune system that focuses directly on tackling cancer. It has already been shown to be highly effective in tackling other forms of the disease, including skin and lung cancer.

The new study involved trial of 258 men, and the trial was conducted jointly by the Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust. All participants had metastatic, recurrent prostate cancer and were treated with the anti-hormone therapy abiraterone and the steroid prednisone.

United Kingdom doctors have discovered that immune system boosting drugs have shown success rates in saving the life of men who are suffering with terminal prostate cancer diagnosis. In many of them, the cancer had spread to their bones, usually a sign there is no more hope. And one in ten were still actively benefiting from treatment.

In the United Kingdom, the disease is the most common cancer in men and it has recently overtaken breast cancer to become the third biggest killer. Some were nearly too unwell to have any treatment at all and they have been resurrected'.

The new trial relates to immunotherapy drugs. As a result, there is insufficient evidence about possible differences in treatment efficacy and side effects by race.

"One of the major challenges with immunotherapy is that we don't have many reliable tests to pick out who will benefit", added Professor Paul Workman, chief executive of The ICR.

"In the last few years immunotherapy has changed the way we treat many advanced cancers - but up to now no one had demonstrated a benefit in men with prostate cancer". These findings show the glimmer of promise for them'.

An early stage trial, presented at the world's biggest meeting of cancer doctors and scientists in Chicago, is the first to show that this approach works on prostate cancer too. Still, the authors said the study suggests a potential strategy for new therapies and hormonal treatment regimens that could narrow the prostate cancer survival disparity between blacks and whites.

He says he's now planning out the next 20 years of his life, not the next two. AA plus leuprolide improved biochemical recurrence-free survival relative to leuprolide alone regardless of pretreatment PSA level, Gleason score, pathology, time to relapse from treatment, and definitive treatment type.

The tests picked up nearly 90 per cent of late-stage cancers.